Well Referenced

Tag: HER2-Negative

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

This 2021 randomized pilot trial compared neoadjuvant everolimus plus letrozole (NET) with standard chemotherapy (FEC) in 40 postmenopausal women with ER-positive, HER2-negative breast cancer. The NET arm demonstrated a higher ultrasound response rate (65% vs. 40%) and better treatment completion (90% vs. 70%) compared to the FEC arm. Additionally, NET

Read More »
June 26, 2025 No Comments

Endocrine therapy initiation and overall survival outcomes with omission of radiation therapy in older Medicare patients with early-stage hormone-receptor-positive breast cancer

This 2022 population-based study analyzed data from the SEER-Medicare database to assess endocrine therapy (ET) initiation and overall survival (OS) among women aged 70–90 with early-stage, hormone receptor-positive, HER2-negative breast cancer who underwent lumpectomy without radiation therapy between 2010 and 2015. Of 2,618 patients, 30.9% did not initiate ET. Logistic

Read More »
June 26, 2025 No Comments

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial

This phase 2 trial investigates the activity and safety of enobosarm, an oral selective androgen receptor modulator (SARM), in patients with androgen receptor-positive, estrogen receptor-positive, and HER2-negative advanced breast cancer. The study found that enobosarm demonstrated promising efficacy in improving clinical outcomes with manageable safety risks. These results support further

Read More »
June 26, 2025 No Comments